Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
The Lucid Festival of Magic
Lucid Group threw a spellbinding event to celebrate eleven years of transforming lives with their standout new branding taking centre stage.
Lighthouse Medical Communications US bolster their senior scientific team
Lighthouse Medical Communications US, part of the award-winning Lucid Group of companies, is pleased to announce the appointment of Marc Pondel, PhD as Executive Medical Science Director. Marc will oversee...
Vivid Medical Communications Supports the 10th Anniversary of Rare Diseases Day 2018
Vivid Medical Communications – a newly created rare diseases specialist agency and part of the successful Lucid Group of companies – is a proud supporter of Rare Diseases Day 2018.
The Lucid Festival of Magic – A Spellbinding Event for All
The Lucid ‘Festival of Magic’ was a celebration of their pioneering work and the people that made it possible.
Eleven Magical Years for Lucid Group
Lucid Group celebrated their eleventh birthday today. They served up plenty of cake and excitement, distributing invitations for family and friends to attend the Lucid Magic festival, which is being...
A Magical Makeover for Lucid Group
Lucid launch their new company branding
Lucid look set to expand their Macclesfield team
This week Business Unit Heads from Lucid Group met with potential candidates at their Macclesfield office to interview for a number of key roles within the organisation. The recruitment drive...
Lucid present their ambitious plans to spread their magic across the industry
Lucid held their first breakfast meeting with top industry recruiters from across the UK to discuss their plans for expansion and recruitment for the year ahead. CEO and Co-Founder Dennis...
Lucid Futures Academy –The Class of 2018
After the success of last year’s Futures Academy, a new intake of graduates is fulfilling their dreams and ambitions as they embark this week on an intensive eight-week training course...
Celebrating a magical year at the Lucid Winter Meeting
In the frosty sunlight of a winter morning, employees from across the Lucid Group gathered to celebrate a magical year of success at the Lucid Annual Winter Meeting. Traditionally being...